As prostate cancer progresses, tumors lose the androgen receptor (AR) on which initial treatment is based. Oftentimes, such patients also lose expression prostate-specific membrane antigen (PSMA), which is the target of approved agent Pluvicto (lutetium (177Lu) vipivotide tetraxetan; Novartis AG) as well as a number of experimental drugs. Such patients can no longer benefit from either androgen- or PSMA-directed therapy. Read More

Researchers from Biorchestra Ltd. presented preclinical data for BMD-001, a novel nanoparticle-formulated antisense oligonucleotide (ASO) being developed for the treatment of Parkinson’s disease (PD). miR-485-3p has been previously identified as a pathway and therapeutic target in neuroinflammatory disease, and the potential relevance of this target in PD was further confirmed through RNA-Seq and analysis of expression levels in animal models and patients with PD. Read More

Deregulation of enzymes that control lipid turnover such as adipose triglyceride lipase (ATGL) is an essential contributor to nonalcoholic fatty liver disease. Recent studies suggest that a fraction of the cytosolic pool of ATGL is proteasomal degraded by E3 ligase constitutive photomorphogenesis protein 1 (COP1). Read More

Researchers from Shandong Academy of Agricultural Science reported the discovery of novel pleuromutilin derivatives as potential antibiotic agents. Synthesis and optimization of a series of pyridinium cation-substituted pleuromutilin analogues led to the identification of compound [I] as the lead candidate with potent antibacterial activity. Read More

Investigators from the European Brain Research Institute (EBRI) recently presented data on an immunotherapeutic approach based on the monoclonal antibody (MAb) 12A12 for treating Alzheimer’s disease (AD). Read More

Veru Inc. announced results from an in vitro study evaluating the effects of sabizabulin against a prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. Read More

Arena Pharmaceuticals Inc. and Boehringer Ingelheim Pharma GmbH & Co. KG have jointly patented 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivative G protein-coupled receptor GPR52 agonists. Read More

Defence Therapeutics Inc. says it has successfully established a strategy conjugating mRNA molecules to Accum, the company’s core technology that enables precision delivery of vaccine antigens or antibody-drug conjugates in their intact form to target cells. Read More

Prodrugs of G protein-coupled receptor GPR52 agonists have been reported in a recent Heptares Therapeutics Ltd. patent as potentially useful for the treatment of psychosis, among others. Read More

C-type lectin receptor is a family of molecules consisting of several proteins that recognize a broad spectrum of ligands, such as immunoreceptor tyrosine-based activation motif (ITAM) and immunoreceptor tyrosine-based inhibitory motif (ITIM), and are known to regulate diverse immunological functions. Read More

Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections. Read More

Acerand Therapeutics (Hong Kong) Ltd. has patented pyrimidine-containing dihydropyrazolone derivatives acting as Wee1-like protein kinase (Wee1) inhibitors and reported to be useful for the treatment of cancer. Read More

Lygenesis Inc. and Imagine Pharma Inc. have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The collaboration will leverage Imagine Pharma’s type 1 diabetes activated islet progenitor cells (T1D AIPCs) and Lygenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes. Read More

A recent study investigated the role of neuraminidase 1 (NEU1) in renal fibrosis. Researchers found increased levels of NEU1 in the fibrotic kidneys of patients and two mouse models of renal fibrosis (mice subjected to unilateral ureteral obstruction or administered folic acid). Read More

Medshine Discovery Inc. has prepared octahydropyrazinodiazanaphthyridine dione compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer. Read More

Researchers at The AIRC Institute of Molecular Oncology in Milan have discovered that the targetable enzyme phosphatidylinositol 5-phosphate 4-kinase type-2 β (PIP4K2B) participates in mechanosensing leading to changes in gene expression, nuclear morphology and cellular motility. The expression of PIP4K2B bodes a poor prognosis in cancer patients and PIP4K2B is the sole PIP4K isoform localized to the nucleus. Read More